文献速递免疫规划妇幼与学校卫生

神经发育障碍儿童接种SARS-CoV-2疫苗后的医疗结局:一项六个月随访研究

Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study.
PubMed 文献 · Vaccine · 2023-05-29

这项纵向研究纳入1335名儿童(762名神经发育障碍患儿和573名健康对照),随访180天,比较接种SARS-CoV-2疫苗后的不良结局。倾向评分匹配后(神经发育障碍组311名 vs 对照组311名),神经发育障碍患儿在第一剂疫苗接种后门诊或急诊就诊及儿科神经科门诊就诊的可能性更高,但仅小部分因疫苗相关不良事件就诊。作者结论认为无特定神经发育障碍诊断或用药明确增加疫苗不良效应风险,神经发育障碍儿童可放心接种。

要点

  • 神经发育障碍患儿首剂接种后门诊或急诊就诊及儿科神经科门诊就诊可能性高于对照。
  • 仅小部分儿童因疫苗相关不良效应就诊门诊或急诊。
  • 注意缺陷多动障碍和孤独症谱系障碍与不良结局无关。

核心结论

  • 无特定神经发育障碍诊断或用药明确增加SARS-CoV-2疫苗不良效应风险。
  • 神经发育障碍儿童可放心接种SARS-CoV-2疫苗以保护自身。

研究设计与样本

  • 纵向研究,纳入1335名接种SARS-CoV-2疫苗的儿童,其中神经发育障碍组762名、健康对照组573名。
  • 所有受试者随访180天,结局事件定义为随访期间门诊或急诊就诊。
  • 采用多变量Cox比例风险回归模型比较倾向评分匹配后神经发育障碍组(n=311)与对照组(n=311)的结局差异,并在全部神经发育障碍患儿(n=762)中探索与结局相关的因素。

主要发现

  • 与对照组相比,神经发育障碍患儿在第一剂疫苗接种后门诊或急诊就诊及儿科神经科门诊就诊的可能性更高。
  • 仅小部分儿童因疫苗相关不良效应就诊门诊或急诊。
  • 在全部神经发育障碍患儿中,沟通障碍者门诊或急诊就诊的可能性更高。
  • 儿科神经科门诊就诊与沟通障碍、智力障碍以及哌甲酯和阿立哌唑处方相关。
  • 注意缺陷多动障碍和孤独症谱系障碍与不良结局无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines have been approved for children and adolescents for protecting against SARS-CoV-2 infection. This longitudinal study aimed to compare adverse outcomes after SARS-CoV-2 vaccination in children with neurodevelopmental disorders (ND) (e.g., attention-deficit/hyperactivity disorder [ADHD], autism spectrum disorder [ASD], communication disorders, intellectual disability, and tic disorders) and healthy control children. METHODS: A total of 1335 children who received the SARS-CoV-2 vaccination (762 children with ND and 573 healthy controls) were recruited. All subjects were followed-up for 180 days, and outcome events were defined as outpatient department (OPD) or emergency department (ER) visits during follow-up. Multivariate Cox proportional hazards regression models were used to identify the potential differences in outcomes between the propensity score-matched ND group (n = 311) and the control group (n = 311), and to explore the factors associated with outcomes among all children with ND (n = 762). RESULTS: Compared with the control group, children with ND exhibited a higher likelihood of subsequent OPD or ER visits and paediatric neurology OPD visits after the first dose of vaccination. However, we found that only a small proportion of the children visited the OPD or ER because of adverse vaccination-related effects. Among all children with ND, those with communication disorders showed a higher likelihood of any OPD or ER visit. Paediatric neurology OPD visits were associated with communication disorders, intellectual disability, and methylphenidate and aripiprazole prescriptions. ADHD and ASD were not associated with adverse outcomes. CONCLUSIONS: No specific ND diagnosis or medication use clearly increased the risk of adverse effects of SARS-CoV-2 vaccination. Children with ND can be reassured that the SARS-CoV-2 vaccination is a safe regimen to protect themselves.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wang LJ, Tsai CS, Chou WJ, et al. Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study. Vaccine. 2023. PMID: 37271705. doi:10.1016/j.vaccine.2023.05.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。